262 related articles for article (PubMed ID: 27036494)
1. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.
Chiang CL; Chen YW; Wu MH; Huang HC; Tsai CM; Chiu CH
J Chin Med Assoc; 2016 May; 79(5):248-55. PubMed ID: 27036494
[TBL] [Abstract][Full Text] [Related]
2. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.
Jia W; Gao Q; Wang M; Li J; Jing W; Yu J; Zhu H
Radiat Oncol; 2021 Feb; 16(1):41. PubMed ID: 33622352
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer.
Xu K; Liang J; Zhang T; Zhou Z; Chen D; Feng Q; Xiao Z; Hui Z; Lu J; Wang X; Deng L; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
Thorac Cancer; 2021 Mar; 12(6):814-823. PubMed ID: 33501781
[TBL] [Abstract][Full Text] [Related]
4. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
5. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer.
Ding X; Ji W; Li J; Zhang X; Wang L
Radiat Oncol; 2011 Mar; 6():24. PubMed ID: 21375774
[TBL] [Abstract][Full Text] [Related]
6. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Suh CH; Park HS; Kim KW; Pyo J; Hatabu H; Nishino M
Lung Cancer; 2018 Sep; 123():60-69. PubMed ID: 30089596
[TBL] [Abstract][Full Text] [Related]
7. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
8. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
9. Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
Yu M; Zhao Q; Li Y; Zhang S; Xu Y; Gong Y; Zhu J; Ding Z; Wang J; Peng F; Wang Y; Huang M; Ren L; Lu Y; Liu Y
Cancer Biother Radiopharm; 2018 Dec; 33(10):421-426. PubMed ID: 31050549
[TBL] [Abstract][Full Text] [Related]
10. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Wang Y; Li Y; Xia L; Niu K; Chen X; Lu D; Kong R; Chen Z; Sun J
Clin Transl Oncol; 2018 Mar; 20(3):366-373. PubMed ID: 28776311
[TBL] [Abstract][Full Text] [Related]
11. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
Zhu L; Zou C; Zhang Z; Wang J; Yang L; Rao C; Yang Z; Liang J; Xia B; Shenglin MA
BMC Cancer; 2021 May; 21(1):511. PubMed ID: 33962566
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
13. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
Elamin YY; Gomez DR; Antonoff MB; Robichaux JP; Tran H; Shorter MK; Bohac JM; Negrao MV; Le X; Rinsurogkawong W; Lewis J; Lacerda L; Roarty EB; Swisher SG; Roth JA; Zhang J; Papadimitrakopoulou V; Heymach JV
Clin Lung Cancer; 2019 Jan; 20(1):43-47. PubMed ID: 30343004
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.
Yang X; Mei T; Yu M; Gong Y
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):409-419. PubMed ID: 35747920
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
[TBL] [Abstract][Full Text] [Related]
16. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
[TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
[TBL] [Abstract][Full Text] [Related]
19. Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients.
Yin H; Jia W; Yu J; Zhu H
BMC Cancer; 2024 Feb; 24(1):197. PubMed ID: 38347438
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.
Hwang JA; Lee JY; Kim WS; Song JS; Rho JK; Choi CM; Lee JC
Clin Lung Cancer; 2016 Nov; 17(6):573-580.e1. PubMed ID: 27378173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]